Immunophenotype Rearrangement in Response to Tumor Excision May Be Related to the Risk of Biochemical Recurrence in Prostate Cancer Patients

被引:5
|
作者
Bosas, Paulius [1 ]
Zaleskis, Gintaras [2 ]
Dabkeviciene, Daiva [2 ]
Dobrovolskiene, Neringa [2 ]
Mlynska, Agata [2 ,3 ]
Tikuisis, Renatas [2 ]
Ulys, Albertas [2 ]
Pasukoniene, Vita [2 ,3 ]
Jarmalaite, Sonata [2 ,4 ]
Jankevicius, Feliksas [1 ,5 ]
机构
[1] Vilnius Univ, Fac Med, Inst Clin Med, LT-03101 Vilnius, Lithuania
[2] Natl Canc Inst Lithuania, LT-08406 Vilnius, Lithuania
[3] Vilnius Gediminas Tech Univ, Dept Chem & Bioengn, LT-10223 Vilnius, Lithuania
[4] Vilnius Univ, Life Sci Ctr, Inst Biosci, LT-10257 Vilnius, Lithuania
[5] Vilnius Univ Hosp Santaros Klin, LT-08661 Vilnius, Lithuania
关键词
prostate cancer; prostatectomy; biochemical recurrence; immunophenotyping; ASSISTED RADICAL PROSTATECTOMY; KILLER-CELL ACTIVITY; SUPPRESSOR-CELLS; IMMUNE-RESPONSE; RADIOTHERAPY; LAPAROTOMY; EXPRESSION; GENERATION; RESECTION; OUTCOMES;
D O I
10.3390/jcm10163709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate cancer (PCa) is known to exhibit a wide spectrum of aggressiveness and relatively high immunogenicity. The aim of this study was to examine the effect of tumor excision on immunophenotype rearrangements in peripheral blood and to elucidate if it is associated with biochemical recurrence (BCR) in high risk (HR) and low risk (LR) patients. Methods: Radical prostatectomy (RP) was performed on 108 PCa stage pT2-pT3 patients. Preoperative vs. postoperative (one and three months) immunophenotype profile (T- and B-cell subsets, MDSC, NK, and T reg populations) was compared in peripheral blood of LR and HR groups. Results: The BCR-free survival difference was significant between the HR and LR groups. Postoperative PSA decay rate, defined as ePSA, was significantly slower in the HR group and predicted BCR at cut-off level ePSA = -2.0% d(-1) (AUC = 0.85 (95% CI, 0.78-0.90). Three months following tumor excision, the LR group exhibited a recovery of natural killer CD3 - CD16+ CD56+ cells, from 232 cells/mu L to 317 cells/mu L (p < 0.05), which was not detectable in the HR group. Prostatectomy also resulted in an increased CD8+ population in the LR group, mostly due to CD8+ CD69+ compartment (from 186 cells/mu L before surgery to 196 cells/mu L three months after, p < 001). The CD8+ CD69+ subset increase without total T cell increase was present in the HR group (p < 0.001). Tumor excision resulted in a myeloid-derived suppressor cell (MDSC) number increase from 12.4 cells/mu L to 16.2 cells/mu L in the HR group, and no change was detectable in LR patients (p = 0.12). An immune signature of postoperative recovery was more likely to occur in patients undergoing laparoscopic radical prostatectomy (LRP). Open RP (ORP) was associated with increased MDSC numbers (p = 0.002), whereas LRP was characterized by an immunity sparing profile, with no change in MDSC subset (p = 0.16). Conclusion: Tumor excision in prostate cancer patients results in two distinct patterns of immunophenotype rearrangement. The low-risk group is highly responsive, revealing postoperative restoration of T cells, NK cells, and CD8+ CD69+ numbers and the absence of suppressor MDSC increase. The high-risk group presented a limited response, accompanied by a suppressor MDSC increase and CD8+ CD69+ increase. The laparoscopic approach, unlike ORP, did not result in an MDSC increase in the postoperative period.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients
    Ke, Zhi-Bin
    You, Qi
    Chen, Jia-Yin
    Sun, Jiang-Bo
    Xue, Yu-Ting
    Zhuang, Rui-Bin
    Zheng, Qing-Shui
    Chen, Ye-Hui
    Wei, Yong
    Sun, Xiong-Lin
    Xue, Xue-Yi
    Xu, Ning
    COMPUTERS IN BIOLOGY AND MEDICINE, 2022, 146
  • [2] Aggressiveness and tumor biology in prostate cancer patients with and without biochemical recurrence
    Acosta, Natalia
    Zabaleta, Jovanny
    Varela, Rodolfo
    Mesa, Jorge
    Serrano, Silvia
    Garay, Jone
    Baddoo, Melody
    Nataly, Cruz
    Lucia Combita, Alba
    Carolina Sanabria-Salas, Maria
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (07) : 144 - 145
  • [3] Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer
    Aragon-Ching, Jeanny B.
    Siegel, Robert S.
    Frazier, Harold, II
    Andrawis, Ramez
    Hendricks, Frederick
    Phillips, Michael
    Jarrett, Thomas
    Guebre-Xabiher, Hiwot
    Patierno, Steven
    Simmens, Samuel J.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : E341 - E345
  • [4] Discovery and validation of prostate cancer biomarkers of biochemical recurrence in low-risk prostate cancer patients
    Kohaar, Indu
    Bejar, Kaitlyn
    Young, Denise
    Song, Yingjie
    Jiang, Jiji
    Kagan, Jacob
    Srivastava, Sudhir
    Hernandez, Javier
    Chesnut, Gregory
    Sesterhenn, Isabell A.
    Leach, Robin J.
    Petrovics, Gyorgy
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer
    Autorino, R.
    Lamendola, M. G.
    De Luca, G.
    De Sio, M.
    Giugliano, F.
    D'Armiento, M.
    De Placido, S.
    Conti, P.
    Di Lorenzo, G.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2007, 20 (04) : 765 - 770
  • [6] Development and validation of a circulating tumor cells-related signature focusing on biochemical recurrence and immunotherapy response in prostate cancer
    Zhang, Xuezhou
    Hong, Baoan
    Sun, Zhipeng
    Zhao, Jiahui
    Li, Mingchuan
    Wei, Dechao
    Wang, Yongxing
    Zhang, Ning
    HELIYON, 2023, 9 (12)
  • [7] Imaging tumor lactate is feasible for identifying intermediate- risk prostate cancer patients with postsurgical biochemical recurrence
    Sushentsev, Nikita
    Hamm, Gregory
    Richings, Jack
    Mclean, Mary A.
    Menih, Ines Horvat
    Ayyappan, Vinay
    Cde, Ian G. Mills
    Warren, Anne Y.
    Warren, Y.
    Gnanapragasam, Vincent J.
    Barrett, Tristan
    Barry, Simon T.
    Goodwin, Richard J. A.
    Gallagher, Ferdia A.
    Barret, Tristan
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (49)
  • [8] Nomograms for predicting the risk of biochemical recurrence in patients with prostate cancer after surgery
    Nyushko, K. M.
    Perepukhou, V. M.
    Gavrilova, Y. D.
    Alekseev, B. Ya
    ONKOUROLOGIYA, 2021, 17 (04): : 100 - 110
  • [9] Maximal tumor diameter is not a prognostic factor for biochemical recurrence in patients with prostate cancer.
    van Oort, Inge M.
    Kok, Dieuwertje E.
    Kiemeney, Lambertus A.
    Mulders, Peter F.
    Witjes, J. Alfred
    Hulsbergen-vandeKaa, Christina A.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 381 - 382
  • [10] A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer
    Chen, Jia-Yin
    Huang, Xu-Yun
    Lin, Fei
    You, Qi
    Xue, Yu-Ting
    Lin, Bin
    Zheng, Qing-Shui
    Wei, Yong
    Xue, Xue-Yi
    Li, Xiao-Dong
    Chen, Dong-Ning
    Xu, Ning
    GENOMICS, 2023, 115 (05)